CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Products  /  Key Therapeutic Areas  /  Immunology

KEY THERAPEUTIC AREAS

Immunology

Autoimmune diseases are becoming a global health problem and can be chronic and life-threatening. Statistics show that around 50 Mn in the U.S. itself suffer from autoimmune diseases.

This makes it all the more imperative to fast track their cure. Biocon is pioneering targeted therapies and exploring potential treatments to transform the breakdown of the body’s immunity into a breakthrough medical innovation

null

Novel Biologics

ITOLIZUMAB

Itolizumab is the first novel, humanised anti-CD6 monoclonal antibody to be approved anywhere in the world. It was launched in India in 2013 under the brand name ALZUMAb™, to treat moderate to severe plaque psoriasis.

Itolizumab is the second novel biologic drug that Biocon has taken from ‘lab to market’. It has been out licensed to U.S.-based Equillium, which plans to develop and commercialise the drug in the U.S., Canada, Australia and New Zealand.

Equillium is currently studying Itolizumab under two open U.S. INDs for the treatment of acute graft-versus-host disease (aGVHD) and lupus nephritis, as well as conducting an additional clinical study in uncontrolled asthma in Australia and New Zealand.

Immunosuppressants

Biocon is one of the world’s largest producers of Immunosuppressants

As one of the world’s largest producers of immunosuppressants, Biocon leverages its comprehensive portfolio of topical, systemic and biologic therapies to treat immune-mediated skin diseases like psoriasis, atopic dermatitis and vitiligo.

null

null

Generics

Biocon has a full suite of generic immunosuppressants that include:

  • Tacrolimus
  • Sirolimus
  • Everolimus
  • Pimecrolimus
  • Mycophenolate Mofetil (MMF)
  • Mycophenolate Sodium (MPS)
OUR LEGACY
GENERICS
WHO WE ARE
PRESS RELEASES
OUR CULTURE
Share